80 - 60 - 0 40- o 20- o 0.00 0.01 0.1 00 -20 -40 00 -•-no ab -e-Control HulgG1 m 30 7 -A- m 10 H2 -0-target alone 100 Ab. [pg/mL] (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT IiiimmoinionotiolomoluioluilioluovoimIE (10) International Publication Number WO 2018/158658 Al C (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/IB2018/051067 (22) International Filing Date: 21 February 2018 (21.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/466,918 03 March 2017 (03.03.2017) US (71) Applicant: RINAT NEUROSCIENCE CORP. [US/US]; 230 East Grand Avenue, South San Francisco, California 94080 (US). (72) Inventors: BUCKTROUT, Samantha Lisa; 2783 Gold- en Gate Avenue, San Francisco, California 94118 (US). CHAPARRO RIGGERS, Javier Fernando; 816 North Delaware Street, #411, San Mateo, California 94401 (US). PASCUA, Edward Derrick; 100 Grand Avenue, #1405, Oakland, California 94612 (US). SMITH, Bevin Marie Brady; 3134 Glen Canyon Road, Scotts Valley, California 95066 (US). (74) Agent: WALDRON, Roy F.; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF Figure 4A 1 -1 (57) : The present invention provides antibodies that bind Glucocorticoid Induced Tumor necrosis factor Receptor family 0 related protein (GITR) and methods of using same. The anti-GITR antibodies can be used therapeutically alone or in combination with \' other therapeutics to treat cancer and other diseases. [Continued on next page] WO 2018/158658 Al MIDEDIM1111011111111111111111111111111111111111111011111111101111111111111111111 Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(k) with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) with sequence listing part of description (Rule 5.2(a)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE
ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF